Frankfurt - Delayed Quote EUR

Cipher Pharmaceuticals Inc. (PHE.F)

7.80

+0.30

+(4.00%)

At close: April 25 at 9:39:01 PM GMT+2

Cipher Pharmaceuticals Inc (CPHRF) Q4 2024 Earnings Call Highlights: Record Revenue Surge and ...

Cipher Pharmaceuticals Inc (CPHRF) reports a remarkable 141% increase in net revenue, driven by strategic acquisitions and robust product performance.

GuruFocus.com last month

CPHRF
+3.47%
Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced its financial and operating results for the year ended December 31, 2024.

CNW Group last month

CPHRF
+3.47%
Cipher Pharmaceuticals Inc.'s (TSE:CPH) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Cipher Pharmaceuticals (TSE:CPH) has had a rough three months with its share price down 21%. However, stock prices are...

Simply Wall St. last month

CPHRF
+3.47%
Cipher Pharmaceuticals Schedules Q4 & Fiscal 2024 Earnings Release and Conference Call

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the fourth quarter and fiscal 2024 after the market close on Tuesday, March 18, 2025. The Company will also hold a conference call on Wednesday, March 19, 2025 at 8:30am ET to discuss the results and corporate developments.

CNW Group last month

CPHRF
+3.47%
Cipher Pharmaceuticals Inc. (TSE:CPH) most popular amongst individual investors who own 57%, insiders hold 42%

Key Insights The considerable ownership by individual investors in Cipher Pharmaceuticals indicates that they...

Simply Wall St. 2 months ago

CPHRF
+3.47%
Those who invested in Cipher Pharmaceuticals (TSE:CPH) five years ago are up 883%

Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality...

Simply Wall St. 3 months ago

CPHRF
+3.47%
Cipher Pharmaceuticals Partner Moberg Pharma AB Reports Topline Data in MOB-015 Phase 3 Study

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today that its partner, Moberg Pharma AB ("Moberg"), issued a news release earlier today stating that MOB-015, a product for the treatment of nail fungus, did not meet the primary endpoint in the North American Phase 3 study being conducted by Moberg. The results of the North American Phase 3 study communicated by Moberg today confirm the initial indications previously informed to the market by Moberg, an

CNW Group 4 months ago

CPHRF
+3.47%
Cipher Pharmaceuticals' (TSE:CPH) Sluggish Earnings Might Be Just The Beginning Of Its Problems

The latest earnings report from Cipher Pharmaceuticals Inc. ( TSE:CPH ) disappointed investors. We did some digging and...

Simply Wall St. 5 months ago

CPHRF
+3.47%
Cipher Pharmaceuticals Inc (CPHRF) Q3 2024 Earnings Call Highlights: Revenue Surge and ...

Cipher Pharmaceuticals Inc (CPHRF) reports a 71% increase in net revenue, driven by strong product sales and strategic acquisitions.

GuruFocus.com 5 months ago

CPHRF
+3.47%
Cipher Pharmaceuticals Third Quarter 2024 Earnings: EPS Misses Expectations

Cipher Pharmaceuticals ( TSE:CPH ) Third Quarter 2024 Results Key Financial Results Revenue: US$10.4m (up 71% from 3Q...

Simply Wall St. 5 months ago

CPHRF
+3.47%
Cipher Pharmaceuticals Reports Third Quarter 2024 Results

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced its financial and operating results for the three and nine months ended September 30, 2024.

CNW Group 5 months ago

CPHRF
+3.47%
Cipher Pharmaceuticals Schedules Q3 2024 Earnings Release and Conference Call

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024. The Company will also hold a conference call on Friday, November 8, 2024 at 8:30am ET to discuss the results and corporate developments.

CNW Group 5 months ago

CPHRF
+3.47%
Discovering Three Undiscovered Gems in Canada

The Canadian market has been experiencing a robust year, with the TSX climbing over 17%, reflecting a broader trend of economic growth, favorable central bank policies, and increasing corporate profits. In this context of market strength and optimism, discovering lesser-known stocks that exhibit strong fundamentals and potential for growth can be particularly rewarding for investors seeking to diversify their portfolios.

Simply Wall St. 5 months ago

CPHRF
+3.47%
MAG

CGAU
Cipher Pharmaceuticals Enhances Leadership Team with Appointment of New Chief Business Officer

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today the appointment of Hamed Ghanei as Chief Business Officer ("CBO").

CNW Group 6 months ago

CPHRF
+3.47%
Keynotes and 50 Companies to Present at the Planet MicroCap Showcase: VANCOUVER in association with Small Cap Discoveries on September 25-26, 2024 at the Fairmont Waterfront Vancouver

VANCOUVER, BC / ACCESSWIRE / September 24, 2024 / Planet MicroCap presents the Planet MicroCap Showcase: VANCOUVER taking place on September 25-26, 2024, where 50 MicroCap public and private companies will be presenting at the Fairmont Waterfront ...

ACCESS Newswire 6 months ago

SSLCF

GHIFF

NWVCF
Cipher Pharmaceuticals Down 16% as Partner Moberg Pharma AB Provides Lower Than Expected Study Results

Cipher Pharmaceuticals Down 16% as Partner Moberg Pharma AB Provides Lower Than Expected Study Results

PREMIUM
MT Newswires 7 months ago

MOB.ST

CPHRF
+3.47%
Cipher Pharmaceuticals Partner Moberg Pharma AB Provides Update on MOB-015 Phase 3 Study

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today that its partner, Moberg Pharma AB ("Moberg"), issued a news release earlier today stating that it has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015, a product for the treatment of nail fungus. Moberg has noted that the number of patients who have achieved clinical cure in this blinded subset of patients is lower than its exp

CNW Group 7 months ago

CPHRF
+3.47%
Undiscovered Gems In Canada To Watch This September 2024

Over the last 7 days, the Canadian market has remained flat, but it is up 13% over the past year with earnings forecasted to grow by 15% annually. In this context, identifying stocks with strong growth potential and solid fundamentals can be particularly rewarding for investors.

Simply Wall St. 7 months ago

TRRVF

CPHRF
+3.47%
HMDPF
Three Undiscovered Gems In Canada To Enhance Your Portfolio

The Canadian market has recently seen a dramatic recovery, rebounding from an early August pullback of nearly 5%, driven by a resilient economy and broadening earnings growth. As the focus shifts towards growth amid easing monetary policies, now is an opportune time to explore lesser-known stocks that could offer substantial potential for your portfolio.

Simply Wall St. 7 months ago

CPHRF
+3.47%
HMDPF

TRRVF
Discovering Three Undiscovered Gems in Canada for Your Investment Portfolio

The Canadian market has been navigating a period of anticipation, particularly influenced by global monetary policy signals from events like the U.S. Federal Reserve's Jackson Hole symposium. As investors await clearer direction on interest rates, it's an opportune moment to explore lesser-known stocks that could offer promising potential amidst these evolving economic conditions. In this article, we will uncover three undiscovered gems in Canada that may be well-positioned for growth within...

Simply Wall St. 7 months ago

CPHRF
+3.47%
HMDPF

TRRVF

Performance Overview

Return	PHE.F	S&P/TSX Composite index (^GSPTSE)
YTD	-17.46%	+0.37%
1-Year	+35.65%	+12.91%
3-Year	+362.63%	+17.60%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cipher Pharmaceuticals Inc. (PHE.F)

Cipher Pharmaceuticals Inc (CPHRF) Q4 2024 Earnings Call Highlights: Record Revenue Surge and ...

Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results

Cipher Pharmaceuticals Inc.'s (TSE:CPH) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Cipher Pharmaceuticals Schedules Q4 & Fiscal 2024 Earnings Release and Conference Call

Cipher Pharmaceuticals Inc. (TSE:CPH) most popular amongst individual investors who own 57%, insiders hold 42%

Those who invested in Cipher Pharmaceuticals (TSE:CPH) five years ago are up 883%

Cipher Pharmaceuticals Partner Moberg Pharma AB Reports Topline Data in MOB-015 Phase 3 Study

Cipher Pharmaceuticals' (TSE:CPH) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Cipher Pharmaceuticals Inc (CPHRF) Q3 2024 Earnings Call Highlights: Revenue Surge and ...

Cipher Pharmaceuticals Third Quarter 2024 Earnings: EPS Misses Expectations

Cipher Pharmaceuticals Reports Third Quarter 2024 Results

Cipher Pharmaceuticals Schedules Q3 2024 Earnings Release and Conference Call

Discovering Three Undiscovered Gems in Canada

Cipher Pharmaceuticals Enhances Leadership Team with Appointment of New Chief Business Officer

Keynotes and 50 Companies to Present at the Planet MicroCap Showcase: VANCOUVER in association with Small Cap Discoveries on September 25-26, 2024 at the Fairmont Waterfront Vancouver

Cipher Pharmaceuticals Down 16% as Partner Moberg Pharma AB Provides Lower Than Expected Study Results

Cipher Pharmaceuticals Partner Moberg Pharma AB Provides Update on MOB-015 Phase 3 Study

Undiscovered Gems In Canada To Watch This September 2024

Three Undiscovered Gems In Canada To Enhance Your Portfolio

Discovering Three Undiscovered Gems in Canada for Your Investment Portfolio

Performance Overview